























Inhibitors and photoluminescent probes
for in vitro studies on protein kinases
PKA and PIM












OLIVIER ETEBE NONGA 
 
Inhibitors and photoluminescent probes  
for in vitro studies on protein kinases  























   
Institute of Chemistry, Faculty of Science and Technology, University of Tartu, 
Estonia 
 
Dissertation was accepted for defense of the degree of Doctor of Philosophy in 
Chemistry by the Council of Institute of Chemistry, Faculty of Science and 
Technology, University of Tartu on August 27th, 2021. 
 
Supervisors: Asko Uri, PhD 
 Professor, Institute of Chemistry, University of Tartu 
 
 Erki Enkvist, PhD 
 Associate Professor, Institute of Chemistry,  
University of Tartu 
 
Opponent: Harri Härmä, PhD 
 University Lecturer, Laboratory of Materials Chemistry and 
Chemical Analysis (Department of Chemistry), University 
of Turku, Finland 
 
Commencement: October 26th, 2021 at 14:15, room 1020, 14A Ravila St., 
 Institute of Chemistry, University of Tartu 
 
This research was supported by grants from the Estonian Research Council 
(PRG454 and IUT20-17), from EU ERA-NET TRANSCAN-2 (project 
PROSCANEXO), and Graduate School of Functional materials and techno-
logies receiving funding from the European Regional Development Fund in 







ISBN 978-9949-03-700-1 (print) 
ISBN 978-9949-03-701-8 (pdf) 
 
Copyright: Olivier E. Nonga, 2021 
 
 




LIST OF ORIGINAL PUBLICATIONS  ......................................................  7 
ABBREVIATIONS  .......................................................................................  8 
1. INTRODUCTION  ....................................................................................  10 
2. LITERATURE OVERVIEW  ...................................................................  11 
2.1. Protein kinases  ..................................................................................  11 
2.1.1. cAMP-dependent protein kinase  ............................................  11 
2.1.2. PIM kinases  ............................................................................  12 
2.2. Antibodies  .........................................................................................  13 
2.3. Photoluminescence  ...........................................................................  15 
2.3.1. Förster-type resonant energy transfer  .....................................  16 
2.4. Inhibitors of PKs  ...............................................................................  17 
2.4.1. Monofunctional inhibitors  ......................................................  18 
2.4.2. Bifunctional inhibitors  ............................................................  19 
2.5. Methods for studying inhibitor/PK complexes  .................................  21 
2.5.1. Activity and characterization of inhibitors  .............................  21 
2.5.2. Thermodynamics of inhibitor/PK binding  .............................  23 
2.5.3. Immunosorbent assays  ...........................................................  24 
2.5.4. X-ray crystallographic studies and ligand binding modes  .....  24 
3. AIMS OF THE STUDY  ...........................................................................  27 
4. METHODS  ..............................................................................................  28 
4.1. Competitiveness of mAb(D38C6) and ARC for binding to PKAcα1 28 
4.2. Biochemical assays with measurement of FA or TGLI  ....................  28 
4.3. Co-crystallization, diffraction data collection, and structure 
determination  ....................................................................................  29 
4.4. Solid phase peptide synthesis  ...........................................................  29 
4.5. Surface sandwich assay for PIM-2 measurement  .............................  30 
5. SUMMARY OF RESULTS AND DISCUSSIONS  ................................  31 
5.1. Conformational rearrangements in PKAc (Paper I and unpublished 
data)  ..................................................................................................  31 
5.1.1. Discovery of inhibitory properties of the antibody 
mAb(D38C6) against PKAcα1 ...............................................  31 
5.1.2. TGL properties of ARC-1085 and ARC-1086 in complex 
with PKAcβ1 and S54L-PKAcβ1  ..........................................  33 
5.2. Development of wild-type-sparing inhibitors for S54L-PKAcβ 
(Paper II and unpublished data)  ........................................................  35 
5.3.  Inhibitors and probes for PIM kinases (Paper III)  ............................  39 
5.3.1. Co-crystal structures ARC-1411 and ARC-3126 with PIM-1 ..  39 
5.3.2. Design of new inhibitors and their characterization  ...............  41 
5.4. Development of assays for PKAcα and PIM-2 (Papers I, III, and 
unpublished data)  ..............................................................................  43 
6 
5.4.1. The AbARC assay  ..................................................................  43 
5.4.2. Surface sandwich assay for the measurement of PIM-2 
concentration (AbARC-2 assay)  ............................................  46 
6. CONCLUSIONS  ......................................................................................  49 
REFERENCES  ..............................................................................................  50 
SUMMARY IN ESTONIAN  ........................................................................  60 
ACKNOWLEDGEMENTS  ..........................................................................  62 
PUBLICATIONS  ..........................................................................................  63 
CURRICULUM VITAE  ...............................................................................  177 




LIST OF ORIGINAL PUBLICATIONS 
The current thesis is based on the following original publications, referred to in 
the text by corresponding Roman numerals: 
 
I. O. E. Nonga, D. Lavogina, T. Ivan, K. Viht, E. Enkvist, and A. Uri, 
“Discovery of strong inhibitory properties of a monoclonal antibody of 
PKA and use of the antibody and a competitive photoluminescent 
orthosteric probe for analysis of the protein kinase,” Biochimica et 
Biophysica Acta (BBA) – Proteins and Proteomics, vol. 1868, no. 8, p. 
140427, Aug. 2020. 
II. O. E. Nonga, E. Enkvist, F. W. Herberg, and A. Uri, “Inhibitors and 
fluorescent probes for protein kinase PKAcβ and its S54L mutant, iden-
tified in a patient with cortisol producing adenoma,” Bioscience, Bio-
technology, and Biochemistry, vol. 84, no. 9, pp. 1839–1845, Sep. 2020. 
III. O. E. Nonga, D. Lavogina, E. Enkvist, K. Kestav, A. Chaikuad, S. E. 
Dixon-Clarke, A. N. Bullock, S. Kopanchuk, T. Ivan, R. Ekambaram, 
K. Viht, S. Knapp, and A. Uri, “Crystal structure-guided design of bi-
substrate inhibitors and photoluminescent probes for protein kinases of 
the PIM family,” Molecules, vol. 26 , no. 14, pp. 4353, Jul. 2021. 
 
Author’s contribution: 
Paper I:  The author participated in planning the experiments, optimized and 
applied the developed assay, and participated in writing the manus-
cript. Compounds used in the study were synthesized by co-authors. 
Paper II:  The author participated in planning the experiments, performed all 
the biochemical experiments, interpreted the results, and partici-
pated in writing the manuscript. Compounds used in the study were 
synthesized by co-authors. 
Paper III:  The author participated in planning the experiments, performed 
most of the biochemical characterization of the compounds, and 
wrote the original draft of the manuscript. New compounds used in 




5-TAMRA  5-carboxytetramethylrhodamine 
AA amino acid 
AbARC photoluminescence immunoaffinity assay for PKAcα 
analysis 
AbARC-2 photoluminescence ARC-affinity assay for PIM-2 analysis 
Adc adenosine 4’-dehydroxymethyl-4’-carboxylic acid moiety 
AF647 Alexa Fluor 647® dye 
Ahp 7-aminoheptanoic acid moiety 
Ahx 6-aminohexanoic acid moiety 
Aoc 8-aminooctanoic acid moiety 
AMTH 5-(2-aminopyrimidin-4-yl)-thiophene-2-carboxylic acid 
moiety 
ARC adenosine analog and peptide mimetics conjugate 
ARC-Lum ARC-type probe possessing protein-induced luminescence 
when in complex with protein kinase 







cAMP cyclic adenosine 3’,5’-monophosphate 
CS Cushing’s syndrome 
Cyanine 5 2-[5-(1,3,3-Trimethylindoline-2-ylidene)-1,3-pentadienyl]-
3,3-dimethyl-3H-indolium-1-hexanoic acid 
D1D2 rabbit monoclonal antibody against PIM-2 (clone D1D2) 
DIPEA N,N-Diisopropylethylamine 
DMF N,N-dimethylformamide 
FA fluorescence anisotropy 
FDA U.S. Food and Drug Administration 
FRET Förster-type resonant energy transfer 
HBTU O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HOBt 1-hydroxybenzotriazole 
HPLC high performance liquid chromatography 
IC50 half maximal inhibitory concentration 
IWC index of wild-type–sparing capability 
KD equilibrium dissociation constant determined by direct 
binding 
mAb(D38C6) rabbit monoclonal antibody against PKAcα (clone D38C6) 
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MW molecular weight 
NMM N-methylmorpholine 
PDB Protein Data Bank 
PIM proviral integration site for Moloney murine leukemia virus 
PK protein kinase 
PKA cAMP-dependent protein kinase A holoenzyme 
PKAc catalytic subunit of PKA 
PKAr regulatory subunit of PKA 
QY quantum yield 
TFA trifluoroacetic acid 
TGLI time-gated luminescence intensity 
TIPS triisopropylsilane 




Phosphorylation reaction is an important cellular post-translational protein 
modification procedure that is catalyzed by protein kinases (PKs). Phosphoryla-
tion diversifies the proteome realm in influencing various aspects of normal and 
pathological physiology. Aberrant activity of PKs may be an indication or a 
cause of multiple complex diseases, such as cancer, diabetes, and cardiovascular 
diseases [1]. Therefore, PKs have become important drug targets in the 21st 
century. In last 22 years, more than 71 small-molecule drugs with reported inhi-
bitory potency toward one or several PKs have been approved by the U.S. Food 
and Drug Administration (FDA) for clinical use. Besides, three PKs have been 
reported to be targetable to block SARS-CoV-2 entry in host cells [2] in an 
attempt to tackle COVID-19. 
The number of human PKs catalyzing phosphorylation is 518. They con-
stitute almost 2.5% of proteins coded by the human genome [3]. In addition to 
being potential drug targets, some PKs serve as biomarkers for cancers and 
other diseases since altered expression level or activity of various PKs are 
observed in a variety of malignancies [4]. Thus, there is a growing demand of 
analytical methods to determine the expression level and activity of disease-
driving PKs. Besides, high throughput assays for screening PK inhibitors also 
form an important component of drug development pipeline. 
ARC inhibitors (conjugates of adenosine analogs and peptide mimetics) are 
middle-sized flexible compounds. Discovery of the competitive nature of 
binding of ARCs and the commercial PKAcα antibody mAb(D38C6) to PKAcα 
enabled the development of a specific and sensitive assay for determination of 
kinase concentration in cell lysates. In this thesis, fluorescence anisotropy (FA)- 
and time-gated luminescence intensity (TGLI)-based assays were developed for 
analyzing PKAcβ, a PK involved in formation of the Cushing’s syndrome (CS). 
Furthermore, moderately wild-type – sparing inhibitors for S54L-PKAcβ were 
constructed. Considering the impact that structural information may provide to 
the drug discovery iterative process [5], the first co-crystal structure of PIM 
kinase with ARC inhibitors were resolved and described herein. From these 
data, new inhibitors with optimized structures were constructed and their deri-
vative compounds were applied in diverse assays. 
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2. LITERATURE OVERVIEW 
2.1. Protein kinases 
Protein phosphorylation was discovered by Krebs and Fischer in 1955 [6]. 
Phosphorylation has been found to be a common post-translational modification 
with 500,000 potential phosphorylation sites in the human proteome and 25,000 
phosphorylation events described for 7,000 human proteins [7]. Protein phos-
phorylation is catalyzed by PKs, which catalyze the addition of γ-phosphate 
group from a nucleoside triphosphate (usually ATP) to the protein substrate. 
The addition of negative charges to the substrate protein changes its conforma-
tion, activity, and localization. Thus, it affects the processes that are down-
stream in the signaling cascade. PKs form one of the largest and most important 
“super-families” of proteins, encoded by 2.5% of all human genes [3]. The 518 
human PKs have been classified into 8 groups according to sequence similarity 
of catalytic domains, the presence of accessory domains, and by considering 
modes of regulation. These groups are AGC, CAMK, CK1, CMGC, RGC, STE, 
TK, and TKL. Most PKs share a common eukaryotic PK catalytic domain. The 
remaining atypical PKs belong to several families, some of which have 
structural, but not sequence similarity to eukaryotic PKs [8]. Additionally, PKs 
have been also categorized as Ser/Thr or Tyr specific (phosphorylating) kinases. 
In fact, these phosphorylatable residues are asymmetrically distributed in pro-
teome (85% Ser, 11.8% Thr, and 1.8% Tyr residues) [9]. The phosphorylation 
of Ser or Thr residues is mostly related to metabolism control (e.g. of Ser/Thr 
PKs , AGC kinases, CAMK kinases, etc.); phosphorylation of Tyr residues is 
mainly related to cell growth and division (e.g. of Tyr PKs: ABL kinases, SRC 
kinases, etc.). Dual specific kinases can act as both Ser/Thr and Tyr kinases 
(e.g., DYRK, MAPK). There are some other kinases that phosphorylate side 
chains of other residues in proteins [10]. 
 
 
2.1.1. cAMP-dependent protein kinase 
cAMP-dependent protein kinase (PKA) mediates many physiological responses 
in cells. For instance, it is a key player in steroidogenesis. PKA belongs to the 
AGC group [11] of PKs (63 members), comprising closely related PKs PKA, 
PKG, and PKC. PKA is a tetrameric enzyme composed of a dimer of regulatory 
(PKAr) subunits and dimer of catalytic (PKAc) subunits [12]. Binding of 2 
cAMP molecules to each PKAr molecule activates the dissociation of the tetra-
meric inactive holoenzyme and subsequent phosphorylation of substrates by 
enzymatically active PKAc subunits [13]. The second messenger cAMP is 
always following activation of adenylate cyclase downstream of G protein-
coupled receptors. In humans, PKAr possesses 4 isoforms (PKArIα, PKArIβ, 
PKArIIα, and PKArIIβ) and PKAc has four isozymes (PKAcα, PKAcβ, and 
PKAcγ, and PrKX). PKAr binds the A kinase anchoring proteins (AKAPs), 
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which anchor the holoenzyme at a specific cellular location [13], [14]. Besides, 
mutations in PKAc and PKAr have been associated with several pathologies 
[15], [16]. The point mutation L205R in the gene PRKACA encoding PKAcα 
was found in up to 67% of patients suffering from CS [15]. The point mutation 
S54L in the gene PRKACB encoding PKAcβ was recently found in a female 
patient with severe CS [16]. PKAc being a Ser/Thr PK, its selectivity to Ser 
phosphorylation is altered by the Phe187V mutation [17]. Substrates with a 
phosphorylatable Ser residue form a stable Michaelis complex with wild-type 
PKAc. Furthermore, PKA is an established biomarker in cancer [18], [19]. 
 Human PKAcα has 2 splice variants producing the isoforms PKAcα1 and 
PKAcα2. PKAcα1 is ubiquitously expressed and PKAcα2 is sperm specific 
[20]. PKAcα1 has been extensively studied, it was the first PK to be crystal-
lized, and has served a model for studying other PKs [21]. Roughly 70% of the 
sequence of the PKAc is shared by all PKs [21]. Human PKAcβ has 10 iso-
forms from 10 splice variants, which are PKAcβ1, PKAcβ2, PKAcβ3, PKAcβ4, 
PKAcβ3a, PKAcβ3ab, PKAcβ3abc, PKAcβ4a, PKAcβ4ab, and PKAcβ4abc 
[22], [23]. PKAcβ1 is most abundant in the brain, with low expression level in 
kidney. PKAcβ2 is the largest subunit among all PKAc possessing MW of 46 
kDa, whereas both PKAcα1 and PKAcβ1 have MW of 41 kDa. PKAcβ4ab and 
PKAcβ4abc are human isoforms not identified in any other species [22] so far. 
In addition to the release from the PKAr, the catalytic activity of PKAc is rea-
lized only after two phosphorylation events within its structure: autophospho-
rylation at Ser338 and phosphorylation of Thr197 by PDK1. Free and cataly-
tically active PKAc catalyze the phosphorylation of roughly 100 protein targets 
[24], including CREB at Ser133 with an ATP KM value of 11.2 µM [25]. 
Although PKAcα and PKAcβ not being functionally redundant [23], viruses can 
use them similarly for their invasion into HEK293 cells and mice [26]. 
 
 
2.1.2. PIM kinases 
The PIM family of PKs includes three constitutively active Ser/Thr kinases 
PIM-1, PIM-2, and PIM-3 that all regulate key biological processes from diffe-
rentiation to apoptosis [27]. They belong to the calcium/calmodulin-dependent 
group (CAMK) of PKs (74 members) and are mostly localized in the cytosol 
and nucleus. PIM kinases are tightly regulated at both transcriptional and trans-
lational levels. There is a diversity of signals leading to PIM gene expression, 
e.g. cytokines, growth factors, and mitogenic stimuli in different cell types [28]. 
Janus kinase/signal transducer and activator of transcription and nuclear factor 
κB pathway activation are among the most extensively studied PIM upstream 
regulators. Nevertheless, PIM-1 phosphorylation at residue Tyr218 by 
Tyrosine-protein kinase Etk correlates with an increase in PIM-1 activity [29]. 
PIM kinases phosphorylate roughly 33 protein targets [30], including pro-apop-
totic protein BAD at multiple sites [31]. PIM genes encodes different isozymes. 
PIM-1 is expressed primarily in cells of the hematopoietic and germline 
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lineages and is represented by 33- and 44-kDa isoforms [32]. PIM-2 is widely 
expressed and is represented by 34-, 38-, and 40-kDa isoforms. PIM-3 is 
detected in various tissues and is represented by its 36-kDa isoform. The diffe-
rent isoforms of PIM-1 and PIM-2 are encoded by genes having alternate trans-
lation initiation codons. 
Within its catalytic domain, human Pim-2 is only 61% and 66% identical to 
PIM-1 and PIM-3, respectively. Besides, substrate specificity is also determined 
by the presence of disfavoring residues in the substrate recognition sequence of 
PKs. An example of this specificity is the presence of Pro at the P + 1 position, 
ensuring orthogonal substrate specificity between proline-directed PKs and PKs 
of the AGC or CAMK groups [33]. Consensus recognition sequences of PIM 
kinases and PKAc subunits are Arg-X-Arg-His-Pro-Ser/Thr-Gly [34], [35] and 
Arg-Arg/Lys-X-Ser/Thr-Leu/Ile [36], respectively, where X denotes any residue 
except Asp and Glu. In effect, based on these consensus sequences or the 
specificity determinants, PIM kinases and PKAc are members of basophilic PKs 
(preferring basic and hydrophobic amino acids as the determinants). Michaelis-
Menten constant (KM) values for ATP and Kemptide or Pimtide are reported in 
Table 1. PIM-related kinases in roundworm have been found to regulate sensory 
functions [37]. Due the elevated expression of PIM kinases in hematologic 
cancers, they can serve as disease biomarkers [38]. Furthermore, knockout of all 
PIM kinases leads to impairment in multiple lineages of hematopoietic cells 
[39]. Finally, PIM-1 and PIM-3 have redundant functions for promoting viral 
invasion, whereas PIM-2 does not promote this process due to poor binding to 
the target protein substrate [40]. 
 
 
Table 1. KMapp values for ATP for PKAcα and PIM kinases and KMapp values for 
Kemptide or Pimtide for PKAcα or PIM kinases, respectively 
PK KMapp (ATP), µM KMapp (Kemptide or 
Pimtide), µM 
PKAcα 17± 5a 20 ± 8 a 
PIM-1 400 b 0.034 c 
PIM-2 4 b 1.2 c 
PIM-3 40 b n. d. 
KMapp – apparent Michaelis-Menten constant; n. d. – not determined; a – ref. [41]; b – 




Antibodies belong to the group of Y-shaped antigen-binding proteins called 
immunoglobulins (Ig) that are produced by B-lymphocytes (B-cells) as an 
immunological response to an antigen. Antibodies can recognize specifically an 
amino acid sequence in an antigen molecule termed epitope. Antibodies consist 
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of two identical light (L) chains and heavy (H) chains that are linked together by 
disulfide bridges. The H chains α, δ, ε, γ, and μ determine the class or isotype 
where the antibody belongs: IgA, IgD. IgE, IgG, and IgM, respectively. Among 
Ig-s, IgG is the most abundant antibody in humans. IgG can be split into 4 sub-
isotypes, each with its own effector function [43]. The 150-kDa IgG molecule 
consists of two identical 50-kDa H chains and two identical 25-kDa L chains 
(Figure 1; [44]). Antibodies can also be divided into monoclonal and poly-
clonal, where polyclonal antibodies are a mixture of antibodies that are pro-
duced by different B-cells. Monoclonal antibodies are produced by single B-
cells; therefore, they all bind the same epitope [43]. The first 100–110 amino 
acids (variable region, Fv) of the amino terminal region of the L or H chain 
differ among antibodies of different specificity. The amino acid sequence 
beyond the variable region is constant in all antibody isotypes and it is termed 





Figure 1. Structure of an immunoglobulin G 
 
Primary Ig-s are raised against an epitope in a host species while secondary Ig-s 
are produced in another host against the Fc region’s isotypes of the first species. 
The antigen binding site of an antibody (paratope) is located at the top of each 
of the two outstretched arms (Figure 1). Each site is defined by 6 loops called 
complementarity determining regions (CDR). There are 3 CDRs found on H 
chain (H1, H2, and H3) and 3 on the L chain (L1, L2, and L3) [43], [44]. These 
protein loops complement the shape and amino acid sequence of specific 
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antigens. As a result, they determine the specific antigens to which the antibody 
can and will bind. Besides, vaccination studies have provided proof-of-concept 
that antibodies can protect against viral challenge. However, the efficacy of 
most promising HIV vaccine trials to date is modest. Antibody-drug conjugates 
are a class of biopharmaceutical drugs designed as a targeted therapy that have 
proven efficient for treating cancers. Besides, therapeutic DNA-encoded mono-
clonal antibodies can be produced in vivo and they reduce the facing challenges 
of repeatedly administrating antibodies such as pre-existing immunity, difficult 




Research technologies based on the application of photoluminescence (e.g., 
spectrometry, microscopy, cell sorting) are gaining ever-growing importance in 
biomedical studies [46]. Photoluminescence is an optical emission of photons 
from a molecule that was photoexcited to a higher energy level. As a photo-
luminescent molecule (luminophore) absorbs a photon, its outer electrons are 
raised from the ground state (S0) to some of its higher energy levels (S1 or S2) 
(Figure 2). After spending some time in the electronically excited state, the 
luminophore returns to the ground state either by emitting a photon (fluore-
scence) or by any of the following nonradiative processes: nonradiative dissi-
pation of energy (as heat), intersystem crossing (ISC) to triplet state, resonance 
energy transfer (RET) to another molecule, photobleaching (light-induced 
destruction of a dye while in the excited state), etc. (Figure 2). Upon ISC, the 
electron in excited triplet state (T1) changes its spin orientation to be the same as 
that of the electron that stays in the ground state (S0). The emission from T1 to 
S0 (a forbidden process) is termed phosphorescence [47]. The average fluore-
scence lifetime or decay time (τ), i.e., the average time that the luminophore 
spends in the excited state before emitting a photon, is typically in the order of 
nanoseconds (1–10 ns) for organic fluorophores, whereas the phosphorescence 
lifetime is typically in the range from milliseconds to seconds. The relatively 
slow radiative decay from T1 to S0 if compared to nonradiative deactivation of 
T1 causes the very low phosphorescence quantum yield (QY), i.e., the number 
of the emitted photons relative to the number of absorbed photons. Heavy atoms 
in the structure of the luminophore have positive effect on the transfer to T1 and 
phosphorescence emission [48]. Phosphorescence and fluorescence QY-s can be 
increased by decreasing the temperature leading to slower nonradiative decay 
[47]. “Self-healing” fluorophores have low constant rates of nonradiative pro-




Figure 2. A version of the Jablonski diagram. S0, ground singlet state; S1, first excited 
singlet state; S2, second excited singlet state; T1, first excited triplet state; IC, internal 
conversion; ISC, intersystem crossing; VR, vibrational relaxation. 
 
2.3.1. Förster-type resonant energy transfer 
Förster-type resonant energy transfer (FRET, also used as Förster resonance 
energy transfer) is an inverse sixth-power distance-dependent nonradiative 
energy transfer (Equation 1A) from the exited state 1D of FRET donor lumino-
phore to the exited state 1A of an acceptor luminophore provided that the emis-
sion spectrum of the donor luminophore overlaps with the absorption spectrum 
of the acceptor luminophore and these luminophores are positioned in close 
proximity [49]. 
 𝐴) 𝐸 =    𝐵) 𝐸 = 1 −   𝐶) 𝐸 = 1 −   
Equation 1. FRET efficiency (E) equations. r is the actual distance between donor and 
acceptor and R0 is the Förster distance (where energy transfer is 50%). τD and τDA are 
the luminescence lifetimes of the free donor and the donor in complex with the 
acceptor, respectively. FID and FIDA are the luminescence intensities of the free donor 





The Förster distance (R0) depends on several factors, including the QY of 
donor, refractive index of the solution and the spectral overlap integral of donor 
and acceptor. The typical Förster distance ranges from 1 to 10 nm, and FRET is 
useful to study biological macromolecules, as this distance is comparable to the 
diameters of many proteins and thickness of biological membranes. FRET 
efficiency (E) is defined as proportion of the donor molecules that have 
transferred excitation state energy to the acceptor molecules, which increases 
with decrease in the intermolecular distance between the luminophores [50]. In 
experimental setup, FRET efficiency is calculated based on the change in the 
luminescence lifetimes (time-resolved mode; Equation 1B) or intensities 
(steady-state mode; Equation 1C) of the donor in the absence and presence of 
the acceptor.  
A way of discarding the background nanosecond-lived autofluorescence in 
biochemical and cellular measurements is using rare-earth lanthanides’ chelates. 
As the extinction coefficients of lanthanides are extremely low (less than 10 M–
1cm–1), lanthanide luminescence can be dramatically enhanced by chelating 
lanthanide ions with an appropriate organic ligand (antenna effect) [51]. It is 
proposed that the strongly absorbing chromophore-organic acceptor transfers 
energy from its T1 state to the lanthanide ion. Thereby, lanthanides’ chelates 
reveal long decay lifetime (0.5–3 ms) in aqueous solutions and have found 
widespread use as luminophores in highly sensitive analytical methods, parti-
cularly for homogeneous immunoassays [51]. As FRET donors, lanthanide 
complexes operate at a longer distance (longer Ro) compared to conventional 
organic fluorophores [47]. However, lanthanide chelates (and metal/organic 
ligand complexes in general) are prone to dissociation and/or chelate (ligand) 
exchange, which is of utmost trouble for in vivo applications and restricts the 
choice of chelating agents. 
 
 
2.4. Inhibitors of PKs 
The search for potent and selective PK inhibitor is intensively ongoing in the 
pharmaceutical industry. There are currently 71 small-molecule kinase inhibi-
tors (SMKIs) approved by the FDA and an additional 16 SMKIs approved by 
other regulatory agencies [52]. In 1997, Lipinski et al. analyzed the structures of 
approved oral drugs and postulated “The Rule of Five” for the potential lead 
candidates to proceed to clinical trials [53]. These rules were insightful and 
helped avoid failures in later stages of drug development, however, new know-
ledge acquired in two decades has made it clear that many complex diseases 
need a different approach for successful treatment. 
Inhibitors are divided into different classes based on their origin (natural or 
synthetic), binding character (irreversible or reversible), and positioning of 
inhibitor in the complex with PK (types I–VI). The classification according to 
the positioning of the inhibitor in PK complex is summarized in Table 2. 
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Binding features Reversibility 
(Yes/No) 
Type I Inhibitor binds to the ATP pocket of the active 
conformation of PK 
Yes 
Type I1/2 Inhibitor binds to the ATP pocket of the inactive 
conformation of PK (DFG in) 
Yes 
Type II Inhibitor binds to the ATP pocket of the inactive 
conformation of PK (DFG out) 
Yes 
Type III Inhibitor binds to the site next to ATP pocket (allosteric 
inhibitor) 
Yes 
Type IV Inhibitor binds far away from ATP pocket (allosteric 
inhibitor) 
Yes 
Type V Inhibitor occupies two binding sites (bivalent inhibitor) Yes 
Type VI Inhibitor occupies an active site where it makes covalent 




Chemical probes are usually described as small molecules that are used to study 
and manipulate a biological system such as a cell by reversibly binding to and 
altering the function of a protein within that system [55]. They are complemen-
tary to genetic approaches and can rapidly and reversibly inhibit a protein or a 
protein domain in cells, be used in almost any cell type and reveal temporal 
features of target inhibition. Inhibitors of PKs can serve as chemical probes. 
Photoluminescent probes allow the detection of species of interest (proteins) 
due to a change in their photoluminescence intensity or emission wavelength 
during the recognition event [56]. This change in photoluminescence can arise 
due to a variety of factors. Long-lived emissive photoluminescent probes are 
used in time-resolved bioimaging and biosensing. 
 
 
2.4.1. Monofunctional inhibitors 
Monofunctional inhibitors bind to one pocket only of the protein. Generally, 
they enable or hinder the binding of natural substrates. Mostly, PK inhibitors 
target a specific pocket in its structure. There are generic and selective PK inhi-
bitors binding to the conserved ATP pocket of PKs. Staurosporine and 4,5,6,7-
tetrabromobenzimidazole are examples of generic PK inhibitors. More selective 
inhibitors H89 and IP20 for PKAc [57], or SGI-1776 and AZD1208 for PIM 
kinases [58] have also been developed. These inhibitors have reduced selecti-
vity because they are targeting the conserved ATP pocket of a PK and the lack 
of specificity sets boundaries to their applications. Besides, intracellular con-
centration of ATP is 1–10 mM, hence the inhibition potency of an ATP-com-
petitive inhibitor should be relatively high to compete with such a high concent-
ration of ATP [59]. Allosteric inhibitors show more selectivity than aforemen-
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tioned inhibitors. A category of specific inhibitors are inhibitory, blocking or 
neutralizing antibodies [60]. Most of the inhibitory antibodies have been deve-
loped for extracellular enzymes [61] due to the poor cellular uptake of anti-
bodies. Many monoclonal antibodies are in pharmaceutical use as drugs. In 
AGC group of PKs, several inhibitory antibodies have been produced for PKAc, 
PKG, and PKC [62], [63]. 
The protein-substrate pocket can also be targeted. Several natural inhibitory 
proteins play this role of targeting protein-substrate pocket , e.g., PKAr of PKA. 
In terms of selectivity, the heat-stable natural PK inhibitor (PKI) selectively 
inhibits PKAc [64], without differentiating between PKAc isozymes. Human 
PKI has three isoforms: PKIα, PKIβ, and PKIγ. From PKI, several peptide frag-
ments, of which the most potent has low nanomolar affinity to PKAc have been 
developed [65]. The 5-24 peptide fragment of PKIα (PKI5–24) has been exten-
sively used to study the conformational changes in PKAc arising upon binding 
of PKI and ATP to PKAc. It has been found that almost no entropy change 
accompanied the PKI5–24 binding to PKAc while ATP binding to it caused a 
negative entropy change, suggesting the PK rigidification [66]. PIM kinases can 
be potently bound by cell-penetrating nona-arginine peptide with submicro-
molar affinity [67]. Due to the similarity in recognition sequence of PKAc and 
PIM kinases, the nona-arginine peptide cannot be considered as a selective 
inhibitor. Besides, Nair et al. have reported the aminopyrimidine derivative 
JP11646 as a PIM-selective small molecule and the only known ATP non-com-
petitive inhibitor of PIM kinases [68]. 
The above-mentioned PK inhibitors are reversible, attaching to the PK with 
non-covalent interactions thus allowing the PK it was inhibiting to start working 
again once removed (Table 2). Most of the time, irreversible inhibitors are de-
signed to increase their residence time and potency [69]. Ibrutinib is an example 
of an irreversible inhibitor targeting Cys481 of Bruton tyrosine kinase. It has 
been used to treat rare lymphoma. Many examples of irreversible inhibitors of 
Tyr PKs are found in the literature [70]. Recently, a covalent inhibitor of PKAc 




2.4.2. Bifunctional inhibitors 
Both ATP-competitive and protein substrate-competitive inhibitors have dis-
advantages such as problems with selectivity. To overcome these obstacles, bi-
substrate inhibitors that covalently connect adenosine analog and peptide 
mimetic moieties have been developed. Bisubstrate inhibitors consist of two 
conjugated moieties, each targeted to a different adjacent binding site in the 
active core of the enzyme [72]. In bisubstrate inhibitors, the free energy of its 
binding is the sum of the free binding energy of separate moieties with a 
reduced entropic penalty. In 1991, Ricouart and coworkers reported the first bi-
substrate inhibitor against PKs [73]. 
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2.4.2.1. ARC-photo probes 
Synthetic middle-sized compounds ARCs are conjugates of adenosine analogs 
and peptide mimetics. Based on these compounds, supported by extensive 
structure-affinity studies and X-ray analysis of ARC/PKAcα co-crystals [74]–
[76], ARC-inhibitors have been developed. They simultaneously associate with 
binding sites of both substrates (ATP and substrate protein) and therefore pos-
sess good-to-high affinity for PKAcα and several other basophilic PKs. Based 
on ARC-inhibitors, fluorescent ARC(Fluo) probes were constructed by labeling 
of ARC-inhibitors with fluorophores at their terminal Lys residue [77]. Often 
the requested high-affinity fluorescent probes are lacking in the starting phase 
of a screening campaign. To solve this issue, group-selective ARC(Fluo) probes 
were previously developed for PKAcα and other basophilic PKs [77]. For 
testing by biochemical assays with purified proteins, even non-selective inhi-
bitors with known binding modes to a group of PKs have great potential be-
cause a single photoluminescent probe constructed from such inhibitors can be 
used to screen and characterize inhibitors toward the PKs of this group. Later, 




2.4.2.2. ARC-Lum probes 
The adenosine analog moiety of ARC-Lum probes is a heteroaromatic bicyclic 
or tricyclic fragment with a sulfur or a selenium atom in one of the aromatic 
rings. The heteroaromatic fragment of an ARC-Lum(−) probe binds to the ATP 
pocket of the PK where it possesses phosphorescence emission at 500−750 nm 
upon excitation with a pulse of near-UV radiation [79]. ARC-Lum(Fluo) probes 
are tandem probes that in addition to the phosphor of ARC-Lum(−) probes 
incorporate a fluorescent dye with an absorption spectrum overlapping with the 
phosphorescence spectrum of ARC-Lum(−) probe. The energy of the exited 
triplet state of the donor is transmitted by resonant energy transfer to the accep-
tor dye. In complex with the PK, ARC-Lum(Fluo) probes possess enhanced 
photoluminescent signal compared to ARC-Lum(−) probe with long (τ = 20 – 
250 µs in the presence of dissolved molecular oxygen) decay lifetime upon their 
excitation with a flash of near-UV radiation [79]. ARC-Lum(Fluo) probes are 
used as tracers for measurements with TGLI or FA readout. In TGLI mode, PK-
induced long lifetime luminescence of ARC-Lum(Fluo) probes allows working 
high concentrations of the probes to shift displacement curves of tested inhibi-
tors away from the tight-binding region to determine their affinity values [80]. 
TGLI measurement allows discarding the short-lived autofluorescence of cells 




2.5. Methods for studying inhibitor/PK complexes 
2.5.1. Activity and characterization of inhibitors 
The PK activity refers to the number of moles of product formed per unit of 
time. It is expressed in enzyme units (U), where 1 U equals the amount of PK 
that phosphorylates 1 nanomole of a specific substrate within 1 minute at 30 °C 
[81]. Specific activity is defined as units of activity per milligram of protein. 
Specific activity is useful for following the purity of an enzyme during purifi-
cation procedures. The specific activity increases at each step of the purification 
process. Instead of physiological substrates, a phosphorylatable peptide con-
taining the PK recognition sequence of the substrate can be used [35], [82]. 
Classically, PK activity was assessed by measuring the adsorption of 32P-labeled 
phosphorylated substrate on phosphocellulose paper [83]. To avoid the risk 
related to handling radioactive samples, chromatography methods based on 
fluorophore-conjugated substrate peptides have been developed [82], [84]. 
Catalytic activity profiling has also been performed in a high-throughput 
manner with nanoliter volumes [85]. In these assays, one substrate is taken in 
excess and time monitoring of phosphorylation rate is carried out (Scheme 1A). 
The equation describing the resulting pseudo first-order reaction (Scheme 1B) is 
further simplified by the Michaelis-Menten equation (Scheme 1C), where Vmax = 𝑘 [𝐸]  and KM =   (Table 1). Each of these assays can be applied for 
characterization of inhibitors when the assay is performed in the presence of 
various concentrations of the inhibitor (Scheme 1A). A competitive inhibitor 
competes with the substrate for binding to the enzyme’s active site (Scheme 1A) 
and its inhibition constant Ki (Scheme 1D) is a measure of its inhibition po-
tency. In increasing the concentration of the competitive substrate, the 
probability of inhibitor binding decreases and Vmax will still be reached for a 
given [E]t at high enough substrate concentration. 
 
A) 𝐸𝐼 + 𝑆 ⇋  𝐼 + 𝐸 + 𝑆 ⇌ 𝐸𝑆 + 𝐼 ⟶ 𝐸 + 𝑃 + 𝐼 
 
B) 𝑣 = [ ] [ ] [ ]       C) 𝑣 = [ ]  [ ]          D) 𝐾 =  [ ][ ][ ]  
 
Scheme 1. Inhibition of enzymatic reaction. A) The monosubstrate reaction mechanism 
in the presence of competitive inhibitor: kcat, the catalytic rate constant of product 
formation; k1, the association rate constant; k–1, dissociation rate constant, koff, 
dissociation rate constant of inhibitor/protein complex; kon, association rate constant of 
inhibitor/protein complex; E, enzyme; S, substrate; P, product; I, inhibitor. B) Equation 
for the rate of monosubstrate reaction: v0, initial velocity; [E]t, the total concentration of 
enzyme; [S], the concentration of substrate. C) Michaelis-Menten equation: KM, 
Michaelis-Menten constant; Vmax, the maximum rate of substrate conversion. D) 
Equation of inhibition constant Ki: [E], concentration of free enzyme; [I], concentration 
of free inhibitor; [EI], concentration of enzyme/inhibitor complex. 
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Binding assays are a convenient alternative to monitoring substrate phosphory-
lation in kinetic assays. Instead of using two substrates, binding of the inhibitor 
to the catalytically active PK is employed. The unlabeled inhibitor can be 
applied in heterogeneous biosensor assays, such as surface plasmon resonance 
(SPR) [86]. SPR yields kinetic parameters for the ligand binding along with the 
value of KD. Conjugation of the ligand with a fluorophore is required for 
obtaining a sensitive homogeneous setup. The resulting fluorescent probe is 
suitable to be used in various fluorescence intensity (FI)-based assays that dis-
tinguish between the free probe and probe/enzyme complex. Methods with 
fluorescence polarization (FP) or FA measurement can be used for determi-
nation of both direct binding of the probe to the PK and displacement of the 
probe from the complex with a PK by an inhibitor [77], [87]. FP and FA are 
interchangeable quantities, while the usage of FA is preferred as it accounts for 
total FI (Equation 2). 
 
A) 𝑝 = ∥∥   B) 𝑟 = ∥∥  
 
Equation 2. p, polarization; 𝐼∥, emission intensity parallel to plane-polarized incident 




FP measurements function based on depolarization of the emission intensity of 
a fluorophore when excited with plane-polarized light. The degree of depolari-
zation is a function of molecular properties, specifically the Brownian mole-
cular rotation, and hence can serve as an effective sensor of molecular complex 
size. In the classical assay format, it is impossible to characterize binders whose 
affinity toward the target protein is higher than that of the fluorescent probe. 
However, in using ARC-Lum(Fluo) probes, measurable IC50 values may be sub-
stantially shifted by the application of a significant excess of probes, compared 
with the target protein, that emit a negligible signal in their free TGLI detection 
mode [79]. Finally, many companies have developed FP-based assay kits: 
BellBrook’s Transcreener™, DiscoveRx’s HitHunter™, Invitrogen’s Far-Red 





2.5.2. Thermodynamics of inhibitor/PK binding 
The first requirement of a promising lead molecule is its sufficient affinity 
toward its target. This affinity is expressed as equilibrium dissociation constant 
(KD) of the complex between target protein (P) and inhibitor (I) (Equation 3). 
 
A) 𝑃 + 𝐼 ⇋ 𝑃𝐼  B) 𝐾 =  [ ][ ][ ]   C) ln 𝐾 = ∆ ° = ∆ ° ∆ °  
Equation 3. Protein-inhibitor interaction characterization. A) Chemical equation of 
protein and inhibitor binding interaction. B) KD, equilibrium dissociation constant of the 
complex P/I: [P], equilibrium concentration of free protein; [I], equilibrium con-
centration of free inhibitor; [PI], equilibrium concentration of protein/inhibitor complex. 
C) ∆𝐺° , standard free energy change of the binding; R, ideal gas constant; T, absolute 




Protein-inhibitor interactions are accompanied with the changes in the free 
energy (∆𝐺° ), enthalpy (∆𝐻° ), entropy (∆𝑆° ), and heat capacity (∆𝐶 ) of the 
system [88]. When the protein-inhibitor interaction is strong, the KD value of 
their complex is small. KD is exponentially proportional to standard free energy 
change of binding, ∆𝐺°  (Equation 3C) that comprises both enthalpic (∆𝐻° ) and 
entropic (∆𝑆° ) changes upon binding. Minimization of ∆𝐺° , thus decrease of 
KD is possible by strengthening interactions (negative ∆𝐻° ) or inflicting dis-
order at the protein-binding interface (positive ∆𝑆° ) upon binding. Strong 
inhibitors make qualitative electrostatic or hydrophobic interactions with their 
protein targets. The thermodynamic characterization of ligand–protein binding 
is most often performed with isothermal titration calorimetry measurements 
[89]. They directly provide full thermodynamic profile of the binding. Valuable 
insight into the binding process can be obtained by combined structural and 
thermodynamic analyses of a set of related complexes. These analyses are able 
to reveal how various effects like the water mediated ligand–protein binding, 
the displacement or trapping of water molecules upon ligand binding, and the 
interplay between hydrogen-bonding and hydrophobic contacts influence the 
thermodynamic balance of binding [88], [89]. 
Inhibitor–protein binding in water is a complex process with various com-
peting enthalpic and entropic contributions. The basic challenge in affinity opti-
mizations can be formulated as to overcome enthalpy–entropy compensation to 
achieve decreased 𝐾 . Optimizing both ∆𝐻° and ∆𝑆°  is frequently conflicting. 
Employing an enthalpic optimization strategy may be beneficial in early-medium 
stages in the drug-discovery process because it will determine the drug quality of 
the compound, and entropic optimization can still be performed in late-stage 
optimization in making inhibitors more rigidified. This rigidification can also alter 
selectivity among PKs [90]. Besides, rigidification can help for better positioning 
the warhead moiety of covalent inhibitors in the complex with PKs [91]. 
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2.5.3. Immunosorbent assays 
Radioimmunoassays were first described in 1959 as a method to study the 
physiology of peptide hormone insulin. In the quest for an alternative method 
not using radioactivity measurement, the enzyme-linked immunosorbent assay 
(ELISA) was introduced in 1970s [92]. ELISA is a widely used diagnostic tool 
in medicine taking advantage of immunoaffinity purification of analytes (hor-
mones, proteins, and antibodies). Additionally, in affinity chromatography, bound 
proteins can be selectively released using a competitive ligand. The major ad-
vantage of ELISA is the use of washing steps, which allow removing the un-
bound material. Hence, because ELISA is a heterogeneous method with several 
washing steps (specialized plate washers for improved repeatability are used) 
and reagent incubations, such method tends to be time-, cost-, and labor-
ineffective. Further, there is a risk of losing the material specifically bound on 
the solid surface. Therefore, the sensitivity of ELISA may suffer from various 
intervening steps and heterogeneity of the sample (e.g., blood). Besides, an 
assay performed with microscopic beads is typically 1000-fold more sensitive 
than the conventional ELISA assays [93]. Finally, a classical ELISA assay 
requires the application of two orthogonal antibodies of the analyte, which are 
not always easy to obtain [94]. 
Protein microarrays, also known as protein chips, are miniaturized and paral-
lel assay systems that contain small amounts of purified proteins. Protein micro-
arrays have been applied for the analysis of antigen–antibody or protein–protein 
interactions [95]. Protein microarrays are made of immobilized molecules (pro-
teins, peptides, or small organic molecules) addressed on glass or polymer 
slides. In functional protein microarrays, the analyte must retain activity and 
remain stable during the experimental steps. Compared with traditional assays, 
the protein chip-based assays have several advantages, i.e., reduction in biolo-
gical sample volume, high sensitivity, ease of performance, and large data gene-
ration [95]. However, microarray immunoassays have kinetic limitations, which 




2.5.4. X-ray crystallographic studies and ligand binding modes 
Apart from using X-ray crystallography, binding modes of inhibitors in proteins 
can be determined in solution by nuclear magnetic resonance (NMR) [97]. As 
of 22 July 2021, 88% of the structures in Protein Data Bank (PDB) were 
obtained by X-ray diffraction analysis but 7.4% of structures were determined 
by solution NMR. A search of the PDB for gene name “PIM1” on 22 July 2021, 
identified 167 PIM-1 crystal structures compared to 329 PKAcα crystal 
structures with gene name “PRKACA” being searched on the same day. These 
numbers account also for mutated kinases of PIM-1 and PKAcα, and holo-
enzymes of PKA. No results of a crystallographic study on PKAcβ and PIM-3 
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have been published up to date. Furthermore, protein crystals contain a large 
amount of solvent (water content 40-60%), allowing relatively free diffusion of 
small compounds through the crystal, allowing keeping the protein in the native 
state. Below, we compared the co-crystal structures of PIM-1 and PKAcα with 








Figure 3. Comparison of interactions of nucleotide molecules bound to ATP-site of 
PIM-1 or PKAcα. A) Co-crystal structure of the kinase domain of PIM-1 with AMP-
PNP (PDB 1XR1). PK is shown as blue cartoon; B) Co-crystal structure of PKAcα with 
ATP (PDB 1ATP). PK is shown as orange cartoon. Residues of PKs forming inter-
actions with the co-crystallized small molecules are shown as lines and are labeled; 
hydrogen bonds are shown as black dotted lines. Mg2+-ions are shown as green spheres. 
Mn2+-ions are shown as magenta spheres. 
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Like in PKAcα, the ATP-binding pocket of PIM-1 is a narrow groove between 
the C- and N-lobes. The KM values of ATP for PIM-1 and PKAcα are given in 
Table 1. The adenine ring of ATP is bound to the hydrophobic cleft locating 
between the lobes. The amino group of adenine ring gives a H-bond with 
Glu121 of both PIM-1 and PKAcα and its nitrogen atom at position 1 gives a H-
bond with Val123 in PKAcα while the corresponding Pro123 in PIM-1 does not 
give such interaction (Pro residue cannot act as a hydrogen bond donor) (Figure 
3). The hydroxyl groups of ribose ring do not interact with PIM-1 residues 
while they interact with PKAcα (Glu127 and Glu170 with 3’-hydroxyl and 2’-
hydroxyl groups, respectively). Furthermore, α-phosphate of the nucleotide is 
coordinated via the conserved Lys67 residue in PIM-1 (Lys72 in PKA) and, at 
the same time, Lys67 forms the salt bridge with Glu89 of αC-helix (the latter is 
a hallmark of active kinase) [98]. Next, in Ser/Thr PKs, γ-phosphate forms a 
charge reinforced hydrogen bond with highly conserved Lys (Lys168 in PKA, 
which interacts with γ-phosphate of ATP, aspartate of HRD, activation loop and 
substrate peptide), and this interaction is required for phosphoryl transfer. In 
PIM-1, the conserved Lys169 does not interact with γ-phosphate of AMP-PNP 
(Figure 3) and the phosphoryl-transfer role is fulfilled by Asp167 [98]. In 
addition to the previously mentioned polar contacts, the nucleotide ring systems 
are stabilized by hydrophobic and π-π interactions with AAs of PIM-1 (e.g., 
Leu44, Val52, Ala65, Leu174, Ile185) [98] and AAs of PKAcα (e.g., Leu49, 
Val57, Val104, Met120, Tyr122, Leu173) [99]. The binding modes of substrate 
peptides in PIM-1 and PKAcα are quite similar [98]. 
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3. AIMS OF THE STUDY 
This study was focused on the construction of inhibitors and fluorescent probes 
as research tools for analysis of PKs in biochemical solutions, cell lysates, and 
living cells. These were the main tasks addressed in the present thesis: 
− Application of protein binding-responsive ARC-Lum(Fluo) probes for 
screening and characterization of inhibitory antibodies for specific regulation 
of activity of PK PKAcα1. 
− Development of a photoluminescent assay for analysis of a new protein 
target PKAcβ1, involved in CS, and construction and characterization of 
wild-type sparing inhibitors for regulation of activity of the mutated protein 
S54L-PKAcβ1. 
− Construction of inhibitors with simplified chemical structure for PK PIM-1, 
guided by results of the first X-ray analyses of crystals of complexes of 
ARC-inhibitors and the protein. Application of the new fluorescent probes, 
inhibitors labeled with fluorescent dyes for microscopy experiments in living 
cells. 
− Development of a sandwich-type assay for specific determination of the 
cancer biomarker PK PIM-2 in biological solutions, based on the cooperative 




4.1. Competitiveness of mAb(D38C6) and  
ARC for binding to PKAcα1 
The assay buffer contained HEPES hemisodium salt (Sigma) (pH 7.4, 50 mM), 
NaCl (Riedel-de Haën) (150 mM), and Tween-20® (Sigma) (0.005%) in the 
presence or absence of ARC-1415 (1 μM), in final volumes of 20 μL in wells of 
384-well low-binding surface microtiter plates (Corning, code 4514), read with 
the PHERAstar microplate reader (BMG Labtech). The assay was performed by 
titrating fixed concentration of the complex of europium chelated streptavidin  
(2 nM) and biotinylated PKAcα1 (1.5 nM) with Alexa Fluor 647-labeled 
mAb(D38C6) and preincubated at 30 °C for 30 min. Measurements were con-
ducted in duplicate, for which standard deviation is depicted. GraphPad Prism 
version 5.04 (GraphPad Software, Inc.) was used for data visualization. 
 
 
4.2. Biochemical assays with measurement of FA or TGLI 
Optical FA measurement modules [ex. 540(20) nm, em. 590(20) nm and 
590(20) nm] and [ex. 590(50) nm, em. 675(50) nm and 675(50) nm] were used 
for orange-fluorescent-dye-labeled and red-fluorescent-dye-labeled probes, 
respectively, in assays with the PHERAstar microplate reader. TGLI measure-
ment modules [ex. 330(60) nm, em. 590(50) nm] and [ex. 330(60) nm, em. 
675(50) nm] were used for orange-fluorescent-dye-labeled and red-fluorescent-
dye-labeled probes, respectively, in assays with the same instrument. The mea-
surement solutions (20 µL volumes) were prepared in black 384-well low-
binding surface microtiter plates (Corning, code 4514) and incubated at 30 °C 
for 20 min before the measurements. The assay buffer contained HEPES hemi-
sodium salt (pH 7.4, 50 mM), NaCl (150 mM), dithiothreitol (Sigma) (5 mM), 
bovine serum albumin (Sigma) (0.5 mg/mL), and Tween-20® (0.005%). 
GraphPad Prism version 5.04 (GraphPad Software, Inc.) was used for data 
analysis with FA [77] or TGLI readout [100]. 
The luminescence decay curves were fitted to the Equation 4. 
 𝐼 = 𝐼 − 𝐼 ∙ 𝑒 + 𝐼  
Equation 4. Fitting luminescence decay data. I is the intensity of the luminescence 
signal measured at time t, I0 is the intensity of the luminescence signal at t = 0, Ibg is the 
intensity of the signal of the background and τ is the luminescence lifetime. 
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4.3. Co-crystallization, diffraction data collection, and 
structure determination 
Final concentrations of PIM-1 and the inhibitors in crystallization solutions 
were 0.1 mM and 1 mM, respectively. Crystals of complexes were grown using 
the sitting-drop vapor-diffusion method at 4 °C with a reservoir solution listed 
in Paper III, Table S1. Diffraction data were collected at Diamond Light 
Source, processed, and scaled with XDS [101] and AIMLESS [102], respecti-
vely. Structures were solved by molecular replacement using Phaser [103] and 
the coordinates of crystal structure of PIM-1 (PDB 2J2I; [104]) as the search 
model. Model rebuilding and structure refinement were performed in COOT 
[105] and REFMAC5 [106], respectively. Data collection and refinement statis-
tics are summarized in Paper III, Table S1. 
 
 
4.4. Solid phase peptide synthesis 
Peptide fragments were prepared by using traditional Fmoc solid phase peptide 
synthesis on Rink amide MBHA resin [67], [107]. Protected amino acids (3 eq.) 
were dissolved in DMF and activated with HBTU/HOBt (2.85 eq. each) and 
NMM (6 eq.) in DMF. After 3 min, the coupling solutions were added to the 
resin and shaken at room temperature (RT) for 40–60 min at RT. The comple-
tion of each coupling step was monitored with the Kaiser test. Removal of N-
terminal Fmoc-group was performed with 20% piperidine solution in DMF (20 
min). After each step, the resin was washed 5 times with DMF. 
The adenosine analog fragments of ARCs are not commercially available 
and smaller equivalents compared to AA were used to save the reagents. 
Carboxylic-acid-functional fragments (1.5 eq.) were mixed with HBTU (2.85 
eq.), HOBt (2.85 eq.) and DIPEA (6 eq.) in DMF and added to the resin (1 eq.), 
and the reaction mixtures were shaken at RT for 60 min. Chloromethyl-
functional fragments (1.5 eq.) in DMF and DIPEA (6 eq.) were added to N-
terminal amino group of the corresponding peptides on the resin (1 eq.) and 
stirred slowly at 60 °C for 8 h. After getting the entire designed compound 
ready on the resin, the cleavage was carried out using the mixture of TFA/ 
H2O/TIPS (90/5/5) for 3 h. The product was collected and evaporated to 
dryness in vacuo. Trituration with methyl-tert-butyl ether was followed by 
another evaporation in vacuo. The products were purified by reversed phase 





4.5. Surface sandwich assay for PIM-2 measurement 
The composition of the assay buffer was as follows: HEPES (50 mM), NaCl 
(150 mM), Tween-20® (0.005%). The Pierce streptavidin-coated microtiter 
plate (#15407) was used for the preparation of the ARC-affinity surface. ARC-
2073 in 10 mM phosphate buffer (pH = 7.0; 80 nM, 50 μL) was added to the 
wells and incubated for 60 min at RT under constant shaking at 300 rpm. All 
the following incubations steps in the assay were performed in the same 
conditions. After each incubation step, the wells were washed with assay buffer 
(100 μL) for 10 s at RT under constant shaking at 300 rpm. All the following 
washing procedures were performed similarly. Thereafter, PIM-2 in assay 
buffer (50 μL) was added to the ARC-affinity wells, incubated, and removed. 
Then, primary antibody D1D2 (1.7 nM, 50 μL) in assay buffer was incubated in 
the wells and removed. Finally, europium chelate-labeled secondary antibody 
(G0506) (2.2 nM, 50 μL) was incubated in the wells and removed from them. 
The wells were washed, dried under fume hood for 10 min and TGLI was 
measured on their surfaces with the PHERAstar microplate reader. GraphPad 
Prism v. 5.04 was used for data analysis. The limit of quantification (LoQ) was 
calculated based on the standard deviation of the calibration curve (SD) and the 
slope of the calibration curve (S) using the equation LoQ = 10 × SD/S. 
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5. SUMMARY OF RESULTS AND DISCUSSIONS 
5.1. Conformational rearrangements in PKAc  
(Paper I and unpublished data) 
5.1.1. Discovery of inhibitory properties  
of the antibody mAb(D38C6) against PKAcα1 
Therapeutic antibodies have been used in the treatment of cancer, autoimmunity, 
and inflammatory diseases [108]. Research with plasma proteases has demon-
strated the potential of inhibitory antibodies for drug development [61]. Besides, 
the neutralizing monoclonal antibody against plasma kallikrein, lanadelumab has 
been approved for treating hereditary angioedema since 2 years [60]. Several 
inhibitory antibodies against PKs of the AGC group have been reported [62] and 
strategies for their cellular uptake have still to be developed. ARCs are bisubstrate 
inhibitors binding to both substrate pockets of PKAcα1 and other PKs [75]–[77]. 
Hereinafter, the isoform PKAcα1 will be denoted PKAcα. 
In attempt to establish the formation of a three-component complex by 
detection of FRET between the PKAcα active site-binding ARC-Lum(Fluo) 
photoluminescent probe and Alexa Fluor 647-labeled antibody mAb(D38C6) 
[mAb(D38C6)-AF647] against PKAcα (ARC/PKAc/Ab), we discovered that 
mAb(D38C6)-AF647 displaced the probe from its complex with PKAcα (Paper 
I, Figure 1). The same behavior was observed in an alternative assay (Figure 4). 
The assay components were europium chelate-labeled streptavidin, biotinylated 
PKAcα and mAb(D38C6)-AF647. Under this format, FRET was detected 
between the europium chelate and Alexa Fluor 647 with an efficiency of 83% 
after excitation with near-UV radiation. The biotinylation of PKAcα at its N-
terminus had no effect on its binding to mAb(D38C6). Application of the 
competitive ARC-inhibitor ARC-1415 (Paper III, Figure 1) led to cessation of 
FRET between the FRET partners because of displacement of mAb(D38C6)-
AF647 from its complex with PKAcα (Figure 4). 
Competitiveness in binding of mAb(D38C6) and ARC-probe to PKAcα 
points to the partially overlapping “epitopes” of the two binders [109]. In other 
words, the association of PKAcα with ARC or mAb(D38C6) leads it to adopt 
two different conformations. ARCs and mAb(D38C6) are bound to the active 
and inactive conformation of PKAcα, respectively. mAb(D38C6) binds to the 
kinase possessing non-ordered conformation of the C-tail. Contrarily to 
mAb(D38C6), association with ATP-pocket binding inhibitors or ATP causes 
PKAcα to adopt an active conformation: C-terminal tail is ordered and Phe327 
residue of PKAcα’s AST region takes part in formation of the ATP pocket 
[110]. Phe327 is an AA in the linear peptide epitope of mAb(D38C6) (raised in 
rabbit against a peptide sequence around Ser326) and it translocates extensively 
when PKAcα is passing from its active conformation to the inactive con-
formation (Paper I, Figure 7). mAb(D38C6) inhibited PKAcα-catalyzed 
reaction between ATP and substrate peptide kemptide with high inhibitory 
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potency (Paper I, Figure 2). The inhibitory potency of mAb(D38C6) was 
calculated by the Cheng-Prusoff equation using KM value of 17 µM for ATP 
(Table 1). Its inhibitory potency (Ki = 2.4 nM) was close to its binding affinity, 
measured via displacement of the probe (KD = 1.2 nM). Furthermore, the IC50 of 
mAb(D38C6) increased approximately 10-fold when increasing the ATP con-
centration 10-fold in a PK inhibition assay (Paper I, Figure S3). Using a 
genetically engineered variant of a cAMP-sensor [76], the non-disruption of 
PKAcα/PKArIIβ complex was confirmed when mAb(D38C6) was applied as an 
ATP-competitive PKAcα inhibitor. 
 














































Figure 4. Competitiveness between mAb(D38C6) and ARC-1415 for the binding to 
PKAcα. FRET between europium chelate-labeled streptavidin (2 nM) interacting with 
biotinylated PKAcα (1.5 nM), and mAb(D38C6)-AF647, without (pink ●) and with 
(green ▲) competitive compound ARC-1415 (1 µM) was measured. Measurement was 
in duplicate, and variance was expressed as standard deviation. 
 
 
Although mAb(D38C6) possesses outstanding inhibitory properties, its use in 
cellular experiments is not possible due to its cellular impenetrability and low 
stability of mAb-s in cellular environment, but also due to its competitiveness 
with ATP present in cells at millimolar concentrations [59]. However, the use of 
mAb(D38C6) is possible in biochemical studies and for measurements in cell 
lysates and bodily fluids [93]. The specific and sensitive AbARC assay was 
developed to determine PKAcα in complicated biological solutions (section 
5.4.1 of this thesis). The majority of PKs lack specific inhibitors; therefore, 
availability of a novel specific research tool has great value for establishment of 
the role of a PKAc isozyme in signaling cascades. For PKAc, a thermostable 
natural inhibitory protein PKI exists [64], [111], but even this inhibitor does not 
differentiate among PKAc isozymes. Inhibitory antibody mAb(D38C6) with 
PKAcα isozyme specificity (Paper I, Figure S4) could be useful for deleting the 
activity of this isozyme in lysates to establish the role of this enzyme as the regu-
33 
lator of protein phosphorylation balances [26]. Such specific inhibitor can also be 
applied to study the non-redundancy in functions of PKAc isozymes [112]. 
In case of other PKs of the AGC group, highly selective inhibitors (like PKI 
for PKAc) are missing. However, several PKs of this group also possess Phe 
residue in the C-tail of the protein that takes part in the formation of the ATP 
pocket in the active conformation of the kinase [113]. Therefore, the approach 
that was tested for mAb(D38C6) might work with other AGC kinases. As ARC-
Lum(Fluo) probes possess high affinity toward many AGC kinases [79], these 
probes that have demonstrated their usefulness for screening and characterization 
of monoclonal antibodies against PKAcα would greatly support studies with other 
AGC kinases. A similar competitiveness phenomenon has been reported before 
[61], showing that N-TIMP-2, an endogenous inhibitor of proteinase MMP-9 
causes the dissociation of the complex of the inhibitory monoclonal antibody Fab 
L13 and catalytic domain of MMP-9. The epitope of the latter antibody is 
restructured and masked by N-TIMP-2. Additionally, other examples of modu-
lation of the activity of various proteins with antibodies by orthosteric, allosteric, 
and parasteric mechanisms have been described [62], [109], [114]. 
 
 
5.1.2. TGL properties of ARC-1085 and ARC-1086 in complex with 
PKAcβ1 and S54L-PKAcβ1 
L205R mutation in PKAcα, found in 67% of patients suffering from CS, leads 
to loss of binding of PKAcα with PKAr [15]. Recently, a somatic mutation was 
identified in the PRKACB gene, encoding PKAcβ1, in a cortisol producing 
adenoma from a female patient with severe CS [16]. This mutation is a 
replacement of Ser54 (AA residue possessing a small and hydrophilic side 
chain) with Leu (AA with a middle-sized and hydrophobic side chain) leading 
to alteration in the structure of GRL (amino acids 48–57), a flexible peptide 
motif that plays a crucial role in the regulation of activity of the enzyme. S54L-
PKAcβ1 is hyperactive at basal level. In the following, PKAcβ1 and S54L-
PKAcβ1 will be denoted PKAcβ and S54L-PKAcβ, respectively. 
ARC-1085 and ARC-1086 are both probes with the same thiophene-com-
prising adenosine analog moiety but possessing a different location of the 
fluorescent dye Alexa Fluor 647 (AF647) in their structures (Scheme 2). In 
ARC-1085, AF647 is attached to the C-terminal D-Lys residue. In ARC-1086, 
AF647 is attached to the chiral spacer D-Lys residue. The location of the FRET 
acceptor AF647 was modified in probes when originally studying protein-
induced long-lifetime luminescence of ARC-Lum(Fluo) probes [79]. It was 
hypothesized that location of the acceptor AF647 would affect the FRET in 
PKAcβ and its mutant PK. If ARC-1085 and ARC-1086 were compared for 
their TGL properties in complex with PKAcβ and S54L-PKAcβ, both ARC-
Lum(Fluo) probes emitted microsecond-scale luminescence upon excitation 
with near-UV radiation if in complex with the kinases (Table 3). Free probes 
revealed negligible long-lifetime signals. 
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Table 3. Relative zero-timepoint luminescence intensity I0 (I0 = 1 for ARC-1085 in 
complex with PKAcβ) and luminescence decay lifetime τDA (µs) for ARC-Lum(Fluo) 
probes in complex with PKs. Final concentrations of the probe of 1 nM and PK of 75 
nM were used 
PKAcβ S54L-PKAcβ 
Compound Io τDA, µs KD, nM Io τDA, µs KD, nM 
ARC-1085 1.00±0.01 136±4 0.06±0.01 0.89±0.01 137±4 0.064±0.010 















































































































Scheme 2. Structures of ARC-1085 and ARC-1086 
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Relative zero-timepoint luminescence intensities (I0) of complexes with PKAcβ 
were slightly higher than those with S54L-PKAcβ (Table 3). Values of 
luminescence decay lifetime of ARC-1085 in complexes with both proteins 
were similar. As expected, ARC-1086 revealed shorter luminescence decay 
lifetime values and higher I0 values compared to ARC-1085 if in complex with 
PKAcβ and S54L-PKAcβ due to shorter distance between the FRET donor and 
acceptor in ARC-1086. Values of luminescence decay lifetime for ARC-1086 in 
complex with PKAcβ and S54L-PKAcβ were 75 µs and 84 µs, respectively 
(Table 3). The difference in I0 and lifetime values indicates the difference in 
binding modes of PKAcβ and S54L-PKAcβ, although having the same affinity 
to ARC-probes (Table 3). Each binding mode leads to a particular rigidified 
double complex [115] protecting the probe differently from molecular oxygen 
quenching [116]. Finally, it can be argued that S54L substitution introduces a 
slightly bigger hydrophobic residue at the tip of GRL of PKAcβ, which makes it 
adopt a more open conformation and position the acceptor dye AF647 further 
from the FRET donor in S54L-PKAcβ complexes. 
 
 
5.2. Development of wild-type-sparing inhibitors for  
S54L-PKAcβ (Paper II and unpublished data) 
Potent inhibitors with wild-type – sparing capability (WC) provide a great tool 
to discriminate between PKAcβ and S54L-PKAcβ in biomedical studies. WC is 
the capacity of the compound to effectively inhibit the phosphorylation 
catalyzed by S54L-PKAcβ and to be less effective against wild-type (wt) 
PKAcβ. The study on novel protein targets PKAcβ and S54L-PKAcβ was 
started with working out a photoluminescence-based binding/displacement 
assay for screening and characterization of inhibitors with using ARC-probes. 
ARCs are conjugates of adenosine analog moiety and peptide mimetic moiety 
tethered by linkers. ARCs of the last generation have a chiral spacer between 
the linkers for proper positioning of the peptide mimetic moiety into the protein 
substrate pocket of PKAcα [72]. The amide group of the chiral spacer makes a 
H-bond with the hydroxyl group of Ser54 in PKAcα [75]. We had hypothesized 
that the disruption of this interaction would help in increasing the index of WC 
(IWC) of the compounds. IWC of a compound is defined as the ratio of KD 
value of the wt PK to KD of the mutated PK. Furthermore, ARC-precursors are a 
fragment of ARC comprising only the adenosine analog moiety, the first linker, 
and the chiral spacer. 
We had previously constructed high-affinity fluorescent probes based on 
ARC inhibitors possessing KD values in picomolar and nanomolar range for 
PKAcα and other basophilic PKs. PKAcα and PKAcβ possess great structural 
similarity, therefore some probes were tested with wt PKAcβ and S54L-PKAcβ 
in a biochemical assay. Titration of fluorescent probes ARC-583, ARC-669, and 
ARC-1085 (Paper II, Table I and Paper II, Table SI) with the purified 
recombinant S54L-PKAcβ revealed KD values of 1.76 nM, 233 pM, and 64 pM 
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for their complexes with the protein, respectively (Paper II, Table I), whereas 
affinity of the probes toward wt PKAcβ was even higher (ARC-583, KD of 160 
pM; ARC-669, KD of 55 pM; ARC-1085, KD of 60 pM). The probe ARC-669 
possesses higher IWC value than ARC-583. ARC-1085 possesses higher IWC 
value than ARC-669 (Paper II, Table I). These ARC-probes were successfully 
applied for the characterization of inhibitors against PKAcβ and S54L-PKAcβ. 
Moreover, we described the first wild-type – sparing inhibitors of S54L-PKAcβ. 
The chirality of the inhibitors 1, 2, 3, and 4 slightly affected their IWC 
(Table 4). The protein targets were able to bind inhibitors that contained either a 
L- or D-amino acid, whereas the conjugates comprising a D-amino acid residue 
(Table 4, compounds 1 and 3) possessed higher affinity than their L-amino acid 
incorporating counterparts (Table 4, compounds 2 and 4). This trend in the 
structure-activity profile of ARCs and ARC-precursors with PKAcβ and S54L-
PKAcβ is like the trend previously reported for ARCs with basophilic PKs 
PKAcα, ROCK-II, and PKGIα [77], [107]. The introduction of the chiral spacer 
4-benzoylphenylalanine comprising a bulky and hydrophobic side chain 
(compounds 3 and 4) led to higher IWC values than the use of D- and L-Lys 
spacers (compounds 1 or 2). Next, variation of the length of α,ω-AA first linker 
of ARC-precursors with another chiral spacer, Arginine, did not lead to an 
enhancement of IWC (compounds 5-7). They possessed constant IWC of 0.2. 
Though, prolonging the first linker led to increased affinity for S54L-PKAcβ 
and its wt protein (Table 4). 
The amide group of the chiral spacer in compound 7 was methylated at the 
amino group yielding compound 8. It revealed 2-fold better IWC value than 
compound 7, as expected. The control compound 9, without methylation of the 
target amino group, revealed the same IWC like compound 8 with a 3-fold 
better affinity toward both PKAcβ and S54L-PKAcβ. Compound 10 does not 
comprise a chiral spacer, but it comprises an amide group between the linkers, 
thus it still contains a H-bond acceptor group in proximity of Ser54. The com-
pound has a low IWC value of 0.3. Use of D-Trp as the chiral spacer yielded 
moderately wild-type−sparing ARC inhibitors (Table 4). Compounds 11 and 12 
revealed similar IWC values of 5.7 ± 1.3 and 4.5 ± 0.7, respectively; Table 4. 
Compound 11 (Paper II, Figure 1) had KD values of 29 nM and 5 nM toward 
PKAcβ and S54L-PKAcβ, respectively (Table 4). However, prolonging com-
pound 12 into the protein substrate pocket (yielding compound 13) worsened 
6.4-fold its IWC, whereas affinity of compound 13 was increased to two-digit 
picomolar range (Table 4). The worsening of IWC is explained by the flexibility 
of both binding partners, PK and ARC: small changes in the structure of ARC 
can lead to great changes in the 3-dimensional structure of the complexed PK 
[75]. It is in line with conformational rearrangement studied with TGLI mea-
surements in section 5.1.2 of this thesis. Prospectively, D-Trp residue can be 
further derivatized in the quest for a more wild-type−sparing ARC-precursor 
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Adc – adenosine-4′-dehydroxymethyl-4′-carboxylic acid moiety; AMTH – 5-(2-
aminopyrimidin-4-yl)-thiophene-2-carboxylic acid moiety; Ahx – 6-aminohexanoic acid 
moiety; Ahp – 7-aminoheptanoic acid moiety; Aoc – 8-aminooctanoic acid moiety; 
Phe(Bz) – para-benzoylphenylalanine; Sar – sarcosine. † – IWC = KD(PKAcβ)/ 
KD(S54L-PKAcβ). Measurements were performed in triplicate and the data variance 
was characterized with the standard error (SE). 
 
 
A generic inhibitor of PKs, staurosporine turned out to be 17-fold more wild-
type sparing than PKAc-selective inhibitor H89 (Table 5). H89 does not induce 
such conformational changes to PKAcα as staurosporine [117]. Inhibitor H89 
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has been used in several biomedical studies involving PKAcβ [26], [114], [118] 
but its affinity to the kinase has not been disclosed. We were the first to report a 
KD value of 1.0 nM for H89 in complex with PKAcβ. A comparison of our FA-
based assay to ADP-Glo™ kinase assay revealed a similar dissociation constant 
for staurosporine to PKAcβ (KD = 0.71 nM vs Ki = 0.67 nM). The WC of inhi-
bitors previously developed to target other basophilic PKs were determined too. 
A derivative of staurosporine and PKC-selective inhibitor, BIM VIII revealed 
very low IWC (smaller than 0.03), which is even lower than that of H89 (IWC 
of 0.07). A PIM-elective inhibitor, SGI-1776 revealed single-digit micromolar 
affinity to both PKAcβ and S54L-PKAcβ (Table 5) with a good WC (IWC = 
0.7). GSK690693, a pan-AKT inhibitor is as wild-type sparing as SGI-1776 
with nanomolar affinity to both PKAcβ and S54L-PKAcβ (Table 5). 
GSK690693 induces conformational changes to AKT PKs [119], which are clo-
sely related to PKAcα. Finally, among tested ATP-competitive inhibitors, 
staurosporine turned out to be the most promising lead compound for develop-
ment of new bisubstrate inhibitors with better WC. 
 
 
Table 5. Dissociation constants (KD), and IWC of H89, staurosporine, BIM VIII, SGI-
1776, and GSK690693 
Compounds 
KD, nM (SE) 
IWC† PKAcβ S54L-PKAcβ 
H89 1.0 (0.1) 14.5 (0.6) 0.07 
Staurosporine 0.71 (0.03) 0.61 (0.06) 1.2 
BIM VIII 2,384 (27) > 73,680 < 0.03 
SGI-1776 1,163 (80) 1,698 (137) 0.7 
GSK690693 61.5 (5.6) 82.5 (4.7) 0.8 
† – IWC = KD(PKAcβ)/KD(S54L-PKAcβ). Measurements were performed in triplicate 
and the data variance was characterized with SE. 
 
 
A study on L205R-PKAcα mutant revealed that PKI5-24 was 338-fold mutant-
sparing [120]. The hydrophobic P + 1 pocket of PKAcα strongly interacts with 
Ile22 of PKI5-24. Similarly, more hydrophobic GRL of S54L-PKAcβ fosters 
interactions (IWC values from 0.7 to 5.7) with compounds 3, 4, 11, 12, and 13, 
all possessing a chiral spacer with a hydrophobic side chain. Furthermore, the 
S54L mutation in PKAcβ renders the mutated kinase non-targetable at Leu54 by 
irreversible inhibitor with the aim [69] of increasing the selectivity. Commer-
cially available synthetic inhibitors usually possess mutant-sparing capability 
instead of WC. Their chemical structures have been optimized for inhibition of 
native proteins. Therefore, a mutation in the ligand-binding region usually leads 
to drug resistance. Thus, up to now the development of wild-type – sparing 
inhibitors for inhibition of mutated proteins is a challenging task. In this study, 
we could develop an inhibitor possessing the highest IWC value of 5.7. 
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5.3. Inhibitors and probes for PIM kinases (Paper III) 
The expression level of PIM kinases is elevated in plasma cell malignancy [4]. 
Thus, recent success in development of PIM-selective inhibitors with low 
picomolar inhibitory potency [42] has intensified clinical testing of these 
inhibitors for the treatment of hematological cancers. ARC-inhibitors confer 
more selectivity to PKs thanks to the bisubstrate approach exploited to develop 
them [72]. Lately, we had developed pan-PIM-selective ARC-inhibitors [67] 
and now we went on with improving them. 
 
 
5.3.1. Co-crystal structures ARC-1411 and ARC-3126 with PIM-1 
Considering the impact that structural information may provide to the drug 
discovery iterative process, we attempted to obtain the first co-crystal structure 
of PIM with ARC-inhibitors. Here, we present the structures of ARC-1411 and 
ARC-3126 with PIM-1. ARC-1411 and ARC-3126 (Paper III, Figure 1) are 
structurally different in their adenosine analog moiety {4-(piperazin-1-yl)-7H-
pyrrolo[2,3-d]pyrimidine vs 8-bromo-2-(methylene)benzo[4,5]thieno[3,2-
d]pyrimidin-4-one, respectively} and the tether between the latter moiety and 
the peptide mimetic moiety (α,ω-nonanedioic acid vs 6-aminohexanoic acid, 
respectively). The PIM-1/ARC co-crystal structures were determined to 1.9-Å 
resolution (Paper III, Table S1). Their coordinates were deposited in the PDB 
(PDB 7OOV for ARC-1411 and PDB 7OOX for ARC-3126). All these struc-
tures feature one protein molecule in the asymmetric unit. 
Importantly, these structures confirm the bisubstrate character of ARC inhi-
bitors for PIM kinases [121], where the adenosine analog and peptide mimetic 
moieties bind to the ATP-pocket and substrate-protein pocket, respectively 
(Figure 5). Considering the structural similarity among PIM kinases, ARCs are 
also bisubstrate inhibitors to PIM-2 and PIM-3 (Paper III, Table 2) and the 
new co-crystal structures with PIM-1 can be used as models for PIM-2 and 
PIM-3. In the co-crystal structures of PIM-1 with ARC-1411 and ARC-3126, 
the adenosine analog moiety of the inhibitors is positioned in the ATP-binding 
site of PIM-1 and the peptide mimetic moiety binds on the protein substrate 
pocket. The peptide mimetic moiety of ARC-1411 is fully resolved in complex 
with PIM-1 compared to the complex with PKAcα [76]. ARC-1411 forms the 
traditional hydrogen bond between the nitrogen atom of pyrrole and the 
backbone of Glu121 of the PK hinge (Figure 5A). This positioning is similar to 
that of AMP-PNP in the crystal with PIM-1 [98]. Contrarily to it, ARC-1411 
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5.3.2. Design of new inhibitors and their characterization 
A new set of ARC-compounds was designed proceeding from the lead com-
pound ARC-3126 (KD,PIM-1 = 1.8 nM; Paper III, Figure 1), because of the 
higher selectivity of its adenosine analog moiety compared to that of ARC-
1411. This affinity value was determined in a binding/displacement assay using 
ARC-1451 (KD,PIM-1 = 2 nM) as the photoluminescent probe (Paper III, Figure 
S2). From the crystal structure data, knowing that D-Arg1, D-Arg4,and D-Arg6 
of ARC-3126 do not make major contacts with PIM-1, these residues were 
removed from the new ARC inhibitors to reduce their complexity and decrease 
their binding to nucleic acids [125] in cells. Potentially, these new structures 
were expected to demonstrate less non-specific binding to components of bio-
chemical assays due to a fewer number of D-Arg residues in them. Besides, D-
Arg4 was replaced by Gly residue to conserve the positioning of D-Arg5. The 
C-terminal D-Lys was retained for potential labeling of inhibitors at this AA. A 
longer linker (8-aminooctanoic acid, Aoc) than that in ARC-3126 (6-amino-
hexanoic acid) was used to account for the approximate dimension of D-Arg1 in 
ARC-3126 and conserve the optimal positioning of the remaining residues 
(Table 6). Different types of the linker were also tested (Table 6). 
Compound 14 (possessing a smaller number of D-Arg residues and Aoc 
linker) revealed a KD value of 11.4 nM compared to KD value of 1.8 nM for 
ARC-3126. The modifications performed on ARC-3126 did not change much 
its affinity toward PIM-1 (Table 6). Besides, PKAcα, another basophilic PK 
binding to Arg-rich ARCs with high-affinity [72], was used in binding/displace-
ment assay for comparison of selectivity of compounds toward PIM-1. Com-
pound 14 was over 50-fold less selective toward PIM-1 than ARC-3126. Next, 
the adenosine analog moiety BPTP in compound 14 was replaced in compound 
15 by BBTP, reported to have high affinity and selectivity to PIM kinases [122]. 
In doing so, the selectivity was increased 9.3-fold from compound 14 to com-
pound 15. The latter compound had a KD value of 0.4 nM to PIM-1 (Table 6). 
Moreover, compounds 14 and 15 are structurally simpler than ARC-3126. From 
the synthesis point of view, they are easier to obtain than ARC-3126. 
ARC-3126 and compounds 14 and 15 were assessed in an inhibition panel of 
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(D-Arg)2-Gly-D-Arg-D-Lys-NH2  > 11,490 > 46,020 > 16,420 > 89,000 
BPTP – 7-bromo-2-(methylene)pyrido[4,5]thieno[3,2-d]pyrimidin-4-one moiety; Ahx – 
6-aminohexanoic acid moiety; Aoc – 8-aminooctanoic acid moiety; BBTP – 8-bromo-2-
(methylene)[1]benzothieno[3,2-d]pyrimidin-4-one moiety; Amt – [4-(aminomethyl)-
1H-1,2,3-triazol-1-yl]acetic acid moiety; Tap – 5-(1H-1,2,3-triazol-4-yl)pentanoic acid 
moiety; Hyp – hydroxyproline. a KD values were determined in binding/displacement 
assays with TGLI or FA readout using probes ARC-1451, ARC-1188, or ARC-583 
[77], [100]. The full structures of ARCs are depicted in Paper III, Table S2. Mean 
values ± SEM are shown (N = 2). 
 
 
PKAcα prefers flexible linkers between the adenosine analog and peptide 
mimetic moieties of ARCs [76]. The linker Aoc in compounds 14 and 15 is 
highly flexible. Rigidified linkers comprising 1,2,3-triazole were tested as alter-
natives to Aoc. Besides, 1,2,3-triazole moieties are attractive tethers because 
they are stable to cellular degradation and capable of hydrogen bonding which 
can improve the inhibitor’s solubility. The compatibility of click chemistry with 
solid-phase peptide synthesis [126] was confirmed for ARC inhibitors by 
producing compounds 16 and 17 incorporating 1,2,3-triazozle linkers (Paper 
III, Supplementary methods). [4-(aminomethyl)-1H-1,2,3-triazol-1-yl]acetic 
acid (Amt) was used in 16 as the linker. The affinity and selectivity of 16 are 
comparable to those of compound 15 (Table 6). Their comparability suggests 
that Aoc and Amt can be interchangeable. The use of another linker, 5-(1H-
1,2,3-triazol-4-yl)pentanoic acid (Tap) yielded compound 17, which has over 
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5.5-fold higher selectivity compared to 16. It has a KD value of 1.8 nM toward 
PIM-1 (Table 6). It has been shown that ARC-inhibitors with hydroxyproline 
(Hyp)-incorporating linkers have better selectivity to PIM kinases [121]. There-
by, 15 was modified by insertion of Hyp between BBTP and Aoc. It resulted in 
compound 18 with over 3.5-fold worse selectivity toward PIM-1 compared to 
15, suggesting a worse positioning of the peptide mimetic moiety of 18 if in 
complex with PIM-1. 
The binding of the distinct peptide mimetic moiety of compounds 14-18 
(PIM peptide) to PIM-1 was also tested. It revealed only weak affinity, pos-
sessing a KD value of over 10 µM (Table 6). 
 Finally, the tested compounds revealed almost the same affinity and selecti-
vity to PIM-3 compared to PIM-1 while they demonstrated lower affinity to 
PIM-2 (except for ARC-3126 which showed similar affinity toward all PIM 
kinases; Table 6). Compounds 15 and 17 were labeled with the fluorescent dye 
Cyanine 5 (Cy5) and 5-TAMRA, resulting in fluorescent probes that were 
capable of crossing the cell plasma membrane (Paper III, Section 2.6). Besides, 
15 was colocalized with fluorescent-protein-tagged PIM-1 (Paper III, Figure 
7). The fluorescence background signal from adsorption of fluorescent probes to 
plastic was lower with Cy5-labeled ARCs, compared to 5-TAMRA-labeled 
probes. If compounds 15 and 17 were labeled with sulfonated Cy5 dye, the 
resulting compounds were not capable of penetrating the cell plasma membrane. 
 
 
5.4. Development of assays for PKAcα and PIM-2  
(Papers I, III, and unpublished data) 
5.4.1. The AbARC assay 
Although the activity level of extracellular PKAcα in the blood serum of cancer 
patients is increased by 5-fold compared to healthy people [19], the con-
centration of PKAcα in serum samples is still very low and thus not detectable 
with routine liquid chromatography/tandem mass spectrometry analysis [127] 
and most of screening assays. Therefore, new sensitive and specific analytical 
assays are needed to assess its expression level and activity in bodily fluids, 
tissue extracts, cell lysates, and cells. So, the AbARC assay was developed for 
this purpose. 
The AbARC assay was constructed utilizing the competitiveness of the 
PKAcα isoform-specific inhibitory antibody with ARC-Lum(Fluo) probes 
(Figure 6). The assay is based on specific capture of PKAcα to mAb(D38C6)-
immobilized immunoaffinity surface and consecutive elution of the bound 
active enzyme from the surface using the high-affinity ARC-Lum(Fluo) probe 
ARC-1063 (Scheme 3; KD value of 10 pM toward PKAcα [100]). The latter 
probe was concomitantly used as the detection reagent. It was possible to 
retrieve PKAcα from the surface with the eluent and nothing eluted from the 
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Figure 7. AbARC assay window in protocol “A” (Paper I, Section 2.4). (A) FA 
readout and (B) TGLI readout without (green ▲) and with (blue ●) immobilization of 
mAb(D38C6)-BTN (6 pmol) onto the streptavidin surface. ARC-1063 (0.09 pmol, 2 
nM) was used as eluent and detection reagent. Measurements were performed in 
triplicate and variance was characterized with SEM. 
 
 
Parameters of association/dissociation kinetics should be considered in con-
structing an end-point binding assay. Dissociation rate of the mAb(D38C6)/ 
PKAcα complex determines how long it takes to reach equilibrium. To be 
applicable for measurements with reasonable waiting time, the processes should 
occur quickly [128]. Short half-lives of elution (2 min; Paper I, Figure S10) 
enabled the development of the fast AbARC assay. Furthermore, ARC-1139 
used in the final version of AbARC assay incorporates a selenophene-com-
prising polycyclic aromatic fragment as the adenosine analog moiety. The 
selenophene-comprising moiety provides higher brightness to the probe, com-
pared with the thiophene-comprising counterpart [79]. Higher brightness is 
beneficial to achieve better sensitivity and lower the limit of quantification 
(LoQ) of the assay. In using the thiophene-comprising probe ARC-1063, the 
lowest amount of PKAcα that could be quantified was 59 fmol. On the other 
hand, in using its selenophene-comprising counterpart ARC-1139, PKAcα 
could be quantified at 25 times lower level (2.3 fmol; Paper I, Figure 5). The 
sensitivity of AbARC assay can be increased in immobilizing mAb(D38C6)-
BTN on microscopic beads [93]. 
AbARC assay keeps the enzyme active thanks to a gentle elution at physio-
logical pH unlike in most immunoprecipitation protocols where the elution is 
performed under acidic conditions. Besides, a solution with low pH value was 
used in inhibition assay to degrade PKAcα and stop catalysis (Paper I, Section 
2.3). The elution in final version of AbARC assay is performed for 10 min in 
reaching the maximal signal (Paper I, Figure S10), while 30 min were 
necessary for reaching only half maximal signal in an alternative assay [129]. 
Three elutions were needed for achieving elution efficiency of 78% in the 
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AbARC assay. These short 10-min cycles permitted the development of the 
timesaving AbARC assay. Differently from ELISA assays, the application of a 
second, orthogonal antibody is not required in the AbARC assay. Instead, a PK 
group-selective photoluminescent probe is used for analysis of PKAcα. ARC-
probes are synthetic organic compounds, and they have the advantage of being 
proteolytically more stable than antibodies. 
Furthermore, the cellular concentrations of PKAcα in cells determined with 
the AbARC assay (Paper I, Figure 6) are close to the PKAcα concentration of 
200 nM in HEK293T cells determined with other methods previously [130]. 
The developed AbARC assay allows specifically determining PKAcα in lysates 
where one molecule of PKAcα is found among 1 200 (HeLa), 17 000 (SKOV-
3), 15 000 (St-T1b), and 12 000 (HCC-44) other protein molecules. Given an 
average MW of eukaryotic cell protein of 50 kDa (BNID 108030; 
www.bionumbers.hms.harvard.edu), these values were obtained from the ratio 
of total protein molar concentration in the lysate determined by Bradford assay 
over PKAcα molar concentration in the lysate determined by AbARC assay 
(Paper I, Figure S9A and S9B). The AbARC assay is economical from the 
point of view of both labor input and use of chemicals. Furthermore, only 35 µg 
of mAb(D38C6)-BTN are needed to analyze 384 samples with the AbARC 
assay. In addition, monoclonal overlapping epitope-competitive antibodies 
against other AGC kinases could be produced at low cost by genetic 
engineering by periplasmic expression of recombinant Fab fragments [61] in 
low cost E. coli expression system [131]. It will permit the adaptation of the 
AbARC assay to other AGC kinases. 
 
 
5.4.2. Surface sandwich assay for the measurement of PIM-2 
concentration (AbARC-2 assay) 
PIM-2 is largely expressed in both leukemia and solid tumors. It plays an im-
portant role in promoting cell survival and preventing apoptosis [133]. There-
fore, new analytical sensitive and specific methods are needed to assess its 
expression level and activity in cells, cell lysates, and tissue extracts. To our 
knowledge, there are few reports on protein analysis assays based on formation 
of a three-component complex [134] on solid surface that use the combination 
of a small-molecule inhibitor and specific antibody as capture/detection re-
agents [135]. 
To establish a sandwich ELISA-adapted assay, we have substituted an ARC-
inhibitor-based capture molecule for the capture antibody. ARC-inhibitors are 
synthetic mid-sized organic molecules which feature several advantages as com-
pared to an antibody, such as shorter generation time, lower costs of manu-
facturing, the lack of batch-to-batch variability, higher modifiability, and better 
thermal stability. Another distinctive feature of the ARC-utilizing assay that 
might be physiologically relevant is that only the active kinase is captured, 
whereas the non-active (e.g., denatured) PIM-2 is washed out during the process. 
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For the surface AbARC-2 assay, ARC-2073, a biotinylated derivative of 
compound 15 was synthesized (Paper III, Table S2). Following immobilization 
of ARC-2073 onto a streptavidin surface, PIM-2 was captured from a solution 
containing the recombinant protein. Thereafter, the captured PIM-2 was 
detected using rabbit anti-PIM-2 antibody D1D2 and visualized with a euro-
pium chelate-labeled secondary goat antibody against rabbit IgG (G0506) 
(scheme of AbARC-2 assay; Paper III, Figure 4A). The emission spectrum of 
G0506 presents several major peaks at 596 nm, 616 nm, and 694 nm (Figure 
8A), with the peak at 616 nm being the highest (main) peak. We had tested 
three commercial filters with two different bandpass widths [590 (50) nm, 615 
(10) nm, and 675 (50) nm] in PHERAstar microplate reader, so to cover these 
peaks. We assessed the sensitivity of the AbARC-2 assay at these peaks (Figure 
8B-C). The sensitivity is the best (slope of curve 6200 a. u. nM-1) in using the 
filter [590 (50) nm] since it covers a part of the main emission peak. Besides, 
non-specific binding of catcher ARC-2073 is negligible here. With no analyte 
PIM-2, there is no signal irrespective of the peak at which the signal is acquired. 
 
 
Figure 8. Europium chelate emission spectrum and calibration curve of the AbARC-2 
assay for measurement of concentration of PIM-2. (A) Time-resolved emission 
spectrum of the europium chelate-labeled secondary goat antibody against rabbit IgG in 
solution. Calibration curve for PIM-2 analysis [immobilized ARC-2073 (4 pmol), 
detection with D1D2 (84 fmol) and G0506 (110 fmol)] obtained with filters 590 (50) 
nm (B), 615 (10) nm (C), and 675 (50) nm (D). Measurements were performed in 











































































s y = 6200x + 180
R2 = 0.98












































s y = 3200x + 110
R2 = 0.98
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With disregard for the filter used, the lowest quantifiable concentration of PIM-
2 was 25 ± 1 pM (quantification range from 25 pM to 625 pM), pointing to high 
sensitivity of the AbARC-2 assay affording the measurement (LoQ) of 1.3 fmol 
(44 pg) of PIM-2 in the sample (50 μL). This sensitivity is thus advantageous 
versus the PIM-2 ELISA kit from ELK Biotechnology (product #ELK6492) 
which has quantification limit of 1.8 fmol. 
To assess the selectivity of the AbARC-2 assay, ARC-2073-coated surface 
was treated with solutions of PIM-1, PIM-3, and DYRK1α (an off-target PK of 
ARC-2073). These kinases were not detected with the pair of detection reagents 
D1D2/G0506 (Paper III, Figure S2) confirming that D1D2 is specifically 
binding to PIM-2. In essence, the developed assay can be used for screening 
antibodies orthogonal to ARC-2073. On the other hand, the developed method 
can be potentially adapted for quantitative detection of PIM-1 or PIM-3 by 
switching to the appropriate primary antibodies. According to the literature, 
D1D2 was used for the specific detection of PIM-2 in cell lysates [136]. Un-
fortunately, the AbARC-2 assay did not work reliably in complex biological 
solutions such as crude cell lysates (Paper III, Figure S3) unlike the original 
AbARC assay, probably due to matrix effects (presence of other biological 
molecules) on the stability of ARC-2073/PIM-2 complex in such solutions. We 
have worked on reversing the AbARC-2 assay format to capture PIM-2 with a 
surface-immobilized antibody to overcome this issue. A reliable calibration 
curve was not obtained in that format. It may be due to hindrance of binding of 
europium chelate-labeled ARC when D1D2 is already bound to PIM-2. This 




The current thesis is focused on the design, synthesis, characterization, and 
application of bifunctional inhibitors of PKs, conjugates of an adenosine ana-
logue heteroaromatic moiety and substrate peptide mimetic D-Arg-rich frag-
ment, covalently tethered by a linker (ARCs). The literature overview briefly 
introduces the basics of PKs, antibodies, photoluminescence, inhibitors of PKs, 
and methods involved in PK studies. These topics are relevant regarding the 
main results of this thesis, which are summarized as follows: 
 Inhibitory properties of the monoclonal antibody mAb(D38C6) were dis-
covered upon screening antibodies against PK PKAcα if using binding-
responsive photoluminescent ARC-Lum(Fluo) probes. The rationale for em-
ploying such inhibitory antibodies in pathologies’ treatment was discussed. 
 Epitope restructuring caused by binding of mAb(D38C6) to PKAcα led to 
dissociation of ARC-Lum(Fluo) probe from the complex with the kinase. 
The discovered phenomenon was used to work-out AbARC assay for the 
analysis of PKAcα in cell lysates. 
 TGLI decay of ARC-1085 and ARC-1086 in complexes with wild-type (wt) 
PKAcβ or its mutated form S54L-PKAcβ shed light on the flexibility of 
these two kinase molecules. FA- and TGLI-based binding/displacement 
assays were developed for screening inhibitors of new protein targets, wt 
PKAcβ and its mutated form S54L-PKAcβ. 
 The effect of different structural elements of inhibitors on PKAcβ/S54L-
PKAcβ selectivity was studied. The use of a hydrophobic chiral spacer in 
ARC led to a wild-type-sparing inhibitor, compound 11, possessing high 
affinity (KD of 5.0 nM for S54L-PKAcβ) and considerable selectivity (IWC 
of 5.7) over the PKAcβ. Structure of compound 11 can further modified to 
increase its IWC. Staurosporine can serve as lead compound for constructing 
of new wild-type-sparing inhibitors. 
 X-ray analysis of PIM-1/ARC co-crystals confirmed the bisubstrate binding 
mode of ARCs to PIM kinases. Guided by crystal structures, structurally 
simplified ARC inhibitors and ARC-based fluorescent probes were 
constructed. New ARC-probes were efficiently taken up by cultured cells. 
Co-localization of the probes with fluorescent protein-fused PIM-1 was 
shown in confocal microscopy experiments in living cells. 
 The AbARC-2 assay was developed for the analysis of PIM-2 protein in bio-
logical solutions with proceeding from the new knowledge about formation 
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SUMMARY IN ESTONIAN 
Inhibiitorid ja fotoluminestsents-sondid proteiinkinaaside PKA 
ja PIM in vitro uuringuteks 
Proteiinkinaasid katalüüsivad valkude fosforüülimist, fosfaatrühma ülekannet 
ATP-lt sihtvalkudele. Proteiinkinaaside normaalsest erinev aktiivsus rakkudes 
võib olla selliste komplekssete haiguste, nagu vähktõbi, diabeet ja südame-vere-
soonkonna haigused, põhjuseks või tunnuseks. Sellest tulenevalt teeb farmaatsia-
tööstus märkimisväärseid jõupingutusi proteiinkinaaside aktiivsuse reguleerimi-
seks inhibiitoritega ning nende ensüümide aktiivsuse jälgimiseks luminestsents-
sondidega. Nende eesmärkide saavutamiseks arendatakse erineva keemilise struk-
tuuriga aineid, väikestest orgaanilistest molekulidest inhibeerivate antikehadeni. 
Viimase veerandsajandi jooksul on ravimiturule jõudnud üle 70 ravimi, mis mõju-
tavad proteiinkinaaside aktiivsust rakkudes. 
Käesolevas töös kasutatud ARC-inhibiitorid on keemiliselt struktuurilt ade-
nosiini matkivate heteroaromaatsete fragmentide ja peptiidide analoogide kon-
jugaadid, neid ühendeid on pikemalt uuritud Tartu Ülikooli keemia instituudis. 
Kasutades uurimisgrupis varem konstrueeritud ARC-Lum(Fluo) fotolumi-
nestsents-sonde näidati käesolevas uurimistöös, et proteiinkinaasi PKA katalüü-
tilise alaühiku α-isovormi (PKAcα) monoklonaalse antikeha (kloon D38C6) 
seondumine sihtvalguga on konkurentne ARC-Lum(Fluo) sondi seondumisega. 
Seejärel selgus, et mAb(D38C6) pärsib kinaasi fosforüülimisaktiivsust madala 
nanomolaarse inhibeeriva toimega (Ki = 2,4 nM). Nimetatud antikeha omadus 
tuleneb sellest, et mAb(D38C6) ja ARC-inhibiitorid (aga ka ATP) seonduvad 
kahe erineva PKAcα konformeeriga. Nende võistlevate PKAcα ligandidega 
[mAb(D38C6) ja ARC] järjestikust töötlemist kasutati tundliku AbARC im-
muunanalüüsi meetodi arendamiseks, mis võimaldas määrata PKAcα väikeseid 
koguseid (alates 93 pg) rakulüsaatides. 
Hiljuti avastati Cushingi sündroomiga patsiendil S54L mutatsiooniga 
PRKACB geen. See mutatsioon viib proteiinkinaasi glütsiinirikka aasa struktuu-
ri muutuseni. Käesoleva uuringu käigus arendati inhibiitor, millel on selle mu-
teerunud proteiinkinaasi suhtes kuuekordne selektiivsus. Lisaks töötati välja 
luminestsentsmeetod, mis võimaldab määrata nii turustatavate kui ka arendata-
vate inhibiitorite afiinsusi PKAcβ valgu suhtes. Uusi fotoluminestsentssonde 
kasutati ka S54L mutatsiooni tulemusena PKAcβ-valgus toimuvate konformat-
siooniliste ümberkorralduste uurimiseks. 
Koostöös Oxfordi ülikooliga viidi läbi ARC-inhibiitorite ja proteiinkinaasi 
PIM-1 komplekside röntgenstruktuuranalüüs. Saadud struktuurimudelitest läh-
tuvalt konstrueeriti lihtsustatud keemilise ehitusega ained. Uued inhibiitorid 
säilitasid madala nanomolaarse toime ja nende mõju oli selektiivne PIM-
kinaaside suhtes. Inhibiitorite märgistamisel fluorestsentsvärvidega saadi PIM-
selektiivsed fluorestsents-sondid, mis läbisid hästi rakkude plasmamembraane. 
Elusrakkude konfokaalmikroskoopia selgitas ARC-sondide jaotuse rakus, mis 
kattus transfekteeritud fluorestsentsvalgu ja PIM-1 liitvalgu paiknemisega. 
61 
Samuti kasutati uusi inhibiitoreid kombinatsioonis PIM-2-spetsiifiliste antikeha-
dega vähi biomarkerite testi AbARC-2 väljatöötamiseks. 
Selles töös konstrueeritud inhibiitorid ja fluorestsents-sondid on mitme-
külgsed keemilised vahendeid proteinkinaaside PKAc ja PIM funktsioonide 
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